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Abstract
Background: The MicroArray Quality Control (MAQC) project evaluated the inter- and intra-
platform reproducibility of seven microarray platforms and three quantitative gene expression
assays in profiling the expression of two commercially available Reference RNA samples (Nat
Biotechnol  24:1115-22, 2006). The tested microarrays were the platforms from Affymetrix,
Agilent Technologies, Applied Biosystems, GE Healthcare, Illumina, Eppendorf and the National
Cancer Institute, and quantitative gene expression assays included TaqMan® Gene Expression PCR
Assay, Standardized (Sta) RT-PCR™ and QuantiGene®. The data showed great consistency in gene
expression measurements across different microarray platforms, different technologies and test
sites. However, SYBR® Green real-time PCR, another common technique utilized by half of all real-
time PCR users for gene expression measurement, was not addressed in the MAQC study. In the
present study, we compared the performance of SYBR Green PCR with TaqMan PCR, microarrays
and other quantitative technologies using the same two Reference RNA samples as the MAQC
project. We assessed SYBR Green real-time PCR using commercially available RT2 Profiler™ PCR
Arrays from SuperArray, containing primer pairs that have been experimentally validated to ensure
gene-specificity and high amplification efficiency.
Results: The SYBR Green PCR Arrays exhibit good reproducibility among different users, PCR
instruments and test sites. In addition, the SYBR Green PCR Arrays have the highest concordance
with TaqMan PCR, and a high level of concordance with other quantitative methods and
microarrays that were evaluated in this study in terms of fold-change correlation and overlap of
lists of differentially expressed genes.
Conclusion: These data demonstrate that SYBR Green real-time PCR delivers highly comparable
results in gene expression measurement with TaqMan PCR and other high-density microarrays.
Published: 11 July 2008
BMC Genomics 2008, 9:328 doi:10.1186/1471-2164-9-328
Received: 26 November 2007
Accepted: 11 July 2008
This article is available from: http://www.biomedcentral.com/1471-2164/9/328
© 2008 Arikawa et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Genomics 2008, 9:328 http://www.biomedcentral.com/1471-2164/9/328
Page 2 of 12
(page number not for citation purposes)
Background
Gene expression research is a rapidly evolving field with
recent advances in technologies aimed at multi-gene
expression profiling and high throughput screening. Tech-
nologies like high-density DNA microarrays enable one to
perform parallel gene expression profiling in the scale of
tens of thousands of genes in a single experiment [1,2].
Quantitative real-time-PCR, though lacking the scale of
microarrays, is a rapid, sensitive and less complex method
for gene expression analysis and offers an alternative
approach for parallel profiling of multiple targets as well
as a time-saving means to validate microarray results.
With many different technologies available for gene
expression measurement, the need to compare the results
obtained from different platforms and technologies and
thus the reliability and biological significance of those
results becomes evident. Moreover, concerns regarding
the reliability and consistency of the microarray technol-
ogy from different suppliers, different test sites and when
using different methods for data processing and normali-
zation have been raised [3-7]. To address those concerns,
scientists from the US Food and Drug Administration
(FDA) established the MicroArray Quality Control
(MAQC) consortium to evaluate the performance of sev-
eral microarray platforms as well as three quantitative
gene expression assays [8-13]. The microarray platforms
were from Affymetrix (AFX), Agilent Techonologies (one-
color protocol (AG1) or two-color protocol (AGL)),
Applied Biosystems (ABI), GE Healthcare (GEH), Illu-
mina (ILM), Eppendorf (EPP) and the National Cancer
Institute (NCI), and the three quantitative assays were
TaqMan®  Gene Expression Assay (Applied Biosystems,
Foster City, CA), Standardized (Sta) RT-PCR™ (Gene
Express, Inc., Toledo, OH) and QuantiGene® (Panomics,
Inc., Fremont, CA).
Reports from the Phase 1 study of the MAQC project,
which profiled two standardized reference RNA samples,
contain important findings on the performance of differ-
ent expression measurement technologies and give
insights into the level of cross-platform comparability
among different technologies [8-13]. The comprehensive
data sets generated from this MAQC effort showed that
great inter-site and cross-platform consistency can be
achieved among different technologies [8,12]. Impor-
tantly, the selection criteria used to define differentially
expressed genes has a substantial impact on the overlap of
the resulting gene lists, with gene lists generated by fold
change ranking being more reproducible than those
obtained by t-test P value ranking. With these findings, the
MAQC Consortium recommends fold change ranking
using a nonstringent P-value cutoff for gene selection.
Another important goal attained by this project is to gen-
erate a thoroughly characterized reference data set against
which new modifications in the existing microarray plat-
forms and other expression measurement technologies
can be compared and validated, and laboratory perform-
ance can be assessed. This was accomplished by providing
the community with two commercially available high-
quality human reference RNA samples that can be used as
a tool for calibration and quality control as well as for per-
formance assessment and validation of assays. The two
RNA samples used in the MAQC project were the Strata-
gene Universal Human Reference RNA (comprised of
RNA from ten different cell lines) and the Ambion
Human Brain Reference RNA. Extremely large lots of these
two reference RNAs were produced under stringent qual-
ity-control procedures. This has allowed researchers to
assess the performance of their assays over time using the
same RNA samples from identical manufacturing lots and
to compare their results with the MAQC data set.
The platforms evaluated in the MAQC project can be cat-
egorized into either hybridization-based or PCR-based
technologies. Different platforms of microarray and
QuantiGene assays belong to hybridization-based tech-
nology. For microarrays, RNA samples are labeled with a
tag (biotin or a fluorophore) followed by hybridization to
immobilized gene-specific probes and fluorophore-based
detection. QuantiGene is a sandwich nucleic acid hybrid-
ization system that detects RNA directly [14]. Targets are
captured through joint hybridization of multiple probes,
and the complex is detected by signal amplification
through a branched DNA amplifier and chemilumines-
cence signal production. TaqMan Gene Expression Assays
and StaRT-PCR are PCR-based techniques. StaRT-PCR is a
competitive end-point PCR-based assay. A standardized
mixture of internal standard (SMIS) competitive tem-
plates is added to the reverse transcribed products prior to
PCR. The individual endpoint StaRT-PCR products are
then separated by size and quantified by high-throughput
microfluidic electrophoresis [15]. The TaqMan assay is
based on real-time PCR using a fluorescent dye to monitor
the amplification of target genes by DNA polymerase. It
employs a target-specific, dual-labeled, fluorogenic
hybridization probe with a quencher on the 3' end to be
hydrolyzed by the 5' to 3' exonuclease activity of Taq
polymerase during the extension step [16].
Real-time PCR is widely considered the gold standard for
gene expression measurement due to its high assay specif-
icity, high detection sensitivity and wide linear dynamic
range. In addition to the TaqMan assay, the SYBR® Green
PCR assay is another commonly used real-time PCR tech-
nique which is employed by half of all real-time PCR users
[17]. Despite its widespread use, this technique was sur-
prisingly not included as part of the MAQC project. SYBR
Green PCR is widely used because of the ease in designing
the assays and its relatively low setup and running costs.BMC Genomics 2008, 9:328 http://www.biomedcentral.com/1471-2164/9/328
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Unlike TaqMan fluorescent probes, SYBR Green dye inter-
calates into double-stranded DNA to monitor the amplifi-
cation of target gene specifically initiated by gene-specific
primers. One drawback of SYBR Green assays, however, is
that the dye is non-specific and can generate false positive
signals if non-specific products or primer-dimers are
present in the assay. Those problems can be addressed by
carefully designing the primers and validating the PCR
products with dissociation curve analysis immediately
after PCR. In addition, other approaches have been prac-
ticed to further increase the specificity of SYBR Green
detection, such as a "hot start" strategy using a DNA
polymerase that requires heat activation, or acquisition of
fluorescence signals at a temperature slightly below the
melting temperature of the desired amplicon but above
which nonspecific primer-dimer related products will
denature and produce minimal signals [18,19].
In the present study, we have evaluated the performance
of SuperArray's SYBR Green real-time PCR assays in profil-
ing the same two reference RNA samples analyzed by the
MAQC Consortium. Using the MAQC data sets available
from the public database [8,12,20], we conducted similar
analyses for the RT2 Profiler PCR Arrays and compared our
expression profiling results with those generated from the
three quantitative technologies (TaqMan, StaRT-PCR and
QuantiGene) as well as from five of the commercial
microarray platforms (AFX, AG1, ABI, GEH and ILM)
examined in the MAQC project [8,12].
Results
Assay Performance of SYBR Green Real-time PCR
To assess the performance of SYBR Green real-time PCR,
the same two reference RNA samples of the identical man-
ufacturing lots as the MAQC study [8,12] were analyzed
using SYBR Green RT2 Profiler PCR Arrays from SuperAr-
ray Bioscience. Sample A was Universal Human Reference
RNA from Stratagene and Sample B was Human Brain Ref-
erence RNA from Ambion. In MAQC phase 1 study, 1297
genes were selected for cross-platform comparisons
between microarrays and the quantitative platforms [8].
Among these 1297 genes, 997, 244 and 205 genes were
assessed by TaqMan, QuantiGene and StaRT-PCR assays,
respectively. The gene list for the custom RT2 Profiler PCR
Array in this study was designed to overlap with the max-
imum possible number of genes for which MAQC data are
available from the three quantitative platforms in the
MAQC project (Table 1). A total of 90 genes were selected,
among which 86 genes overlapped with TaqMan data, 76
genes overlapped with QuantiGene data, and 57 genes
overlapped with StaRT-PCR data. In addition, these 90
selected genes overlapped with data available for 89 genes
on the AFX and ABI, 86 on the AG1, 88 on the GEH, and
87 on the ILM platforms. The custom PCR Array was run
in six technical replicates for each of the two MAQC refer-
ence RNAs (Samples A and B). For cross-platform compar-
isons between SYBR Green PCR Arrays and other gene
expression analysis platforms evaluated in the MAQC
study, data from the other technologies were obtained
from published results [8,12] and from the database
accessible from the MAQC website [20]. The comparison
of performance metrics between SYBR Green PCR Arrays
and the other three quantitative platforms assessed in the
MAQC study is summarized in Additional file 1.
Assay precision
The precision of the SuperArray's SYBR Green real-time
PCR Arrays is assessed by the coefficient of variation (CV)
and standard deviation (SD) of the replicate CT measure-
ments (n = 6 for each assay) from both Samples A and B
(Figure 1 and Table 2). The average CV for the 184 mean
CT values generated from all assays on the custom PCR
Arrays is 0.73%. All assays on PCR Arrays have an average
CT value showing a CV below 5% with 95% of the CT val-
ues having a CV of less than 2% (Figure 1). The replicate
measurements for CT values below 30 show an average
standard deviation within 0.20 cycle (Table 2). As noted
in Figure 1 and Table 2, both CV and SD tend to increase
with increasing CT values (i.e. a decreasing amount of
transcripts); this trend has also been observed for both
TaqMan and StaRT-PCR [8]. The above precision assess-
ment also includes variations from the entire process of
reverse transcription-PCR as each replicate array was per-
formed on cDNA synthesized from individual replicate
reverse transcription reactions. To make a comparison
with the other three quantitative technologies examined
in the MAQC project, the CT values obtained from PCR
Arrays were transformed from a decreasing copy number
scale to an increasing copy number scale applied in the
MAQC study [8]. Using the same assumption as for Taq-
Man PCR where a CT value of 35 corresponds to five tran-
script molecules, the CT  value for 6000 transcript
molecules is extrapolated to be 24.78. This value is calcu-
lated to be 12.55 (log2 6000) on the common MAQC
transformed log2 scale. After data transformation, the CVs
for all 184 assays on PCR Arrays range from 0.18% to
74.36% with a median of 0.89%, and those for assays
detecting > 6000 transcript copies (n = 70) range from
0.19% to 3.16% with a median of 0.57%.
Detection sensitivity
PCR Array quantification is determined by CT numbers. A
gene is considered absent when the average CT exceeds 35.
Among the 90 genes that were assayed with SYBR Green
PCR Arrays, seven genes are considered absent in sample
B with the average CT > 35. These genes are FOXA1,
ABCC2, APOB, APOH, MMP1, RAD51 and TFF1. All of
these genes were considered to be either absent or
expressed at low levels as measured by TaqMan and
QuantiGene [8]. FOXA1 was also noted to be absent byBMC Genomics 2008, 9:328 http://www.biomedcentral.com/1471-2164/9/328
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StaRT-PCR while the other six genes were not included in
the measurements by this method. All genes are present in
Sample A at a level above the limit of quantitation
(referred to as the limit of detection (LOD) in the MAQC
study [8]) of PCR Arrays with the average CT  values
smaller than 35. Hence, 83 out of the 90 selected genes
(92%) are present in both Sample A and Sample B.
Assay range
The assay range is indicated by the difference in signals on
a log10 scale between the highest and the lowest expres-
sion as described previously [8]. The assay range for the
SYBR Green PCR Arrays is 8.6 with CT values ranging from
6.5 for 18S rRNA to 35 for weakly expressed genes.
Inter-site reproducibility
Inter-site comparison of the performance of SYBR Green
PCR Arrays was carried out using the Human Drug Metab-
olism RT2  Profiler™ PCR Array (Cat# APH-002) from
SuperArray Bioscience. For inter-site comparison, the two
MAQC reference RNAs were analyzed on the PCR Array at
two different locations. PCR Arrays were performed on an
ABI 7500 Real-Time PCR System at Site 1 while the arrays
were run on an ABI 7000 at Site 2. Five replicate arrays
Table 1: Gene list of the custom SYBR Green RT2 Profiler PCR Array showing the overlaps with the other three quantitative gene 
analysis technologies
Probes present in all three 
quantitative platforms
Gene Symbol TaqMan and QuantiGene Gene Symbol TaqMan and StaRT-PCR Gene Symbol
1 ABCD2 42 ABCC2 72 ANXA1
2 ADM 43 ABCD1 73 ARHGDIB
3 AES 44 ABCG5 74 ATP1B2
4 ANXA5 45 AFP 75 CDK8
5 BAG1 46 APC 76 DAP 
6 BRCA2 47 APOB 77 ERCC5
7 CCNA2 48 APOH 78 GSTP1
8 CDK9 49 BAG4 79 GSTT1
9 CDKN1A 50 CCL20 80 NTRK3
10 CYP1B1 51 CDK5R1 81 PCNA
11 DAD1 52 CHEK1 82 PPP3CA
12 DPP4 53 CHGA 83 PTCH 
13 FADD 54 COL1A1 84 TP53
14 FGF9 55 CSNK2A2
15 FOXA1 56 DRD5 House Keeping Genes Gene Symbol
16 FURIN 57 EDN1 85 B2M
17 G6PD 58 EGFR 86 ACTB
18 ICAM1 59 EIF2AK2 87 GAPDH
19 IGF2R 60 ERBB4 88 HPRT1
20 IGFBP2 61 GFAP 89 POLR2A
21 IGFBP5 62 IGF2 90 RPL13A
22 IL8 63 IGFBP1
23 INPPL1 64 JAK2
24 JUN 65 JUNB
25 KCNS3 66 KCNC1
26 KDR 67 MIF
27 KIT 68 MMP1
28 LDLR 69 RAD51
29 MAP2K6 70 STAT4
30 MAP3K14 71 TFF1
31 MX2
32 MYB
33 MYC
34 PTGS2
35 RAD52
36 RARA
37 RB1
38 SELE
39 SLC2A1
40 SOD1
41 TYMSBMC Genomics 2008, 9:328 http://www.biomedcentral.com/1471-2164/9/328
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were run for each sample at each site. The average CT value
for each assay was compared between the two sites (Figure
2A and 2B). The results show a high correlation between
CT values obtained from the two sites with R = 0.969 and
0.973 for Sample A and Sample B, respectively (Figure 2A
and 2B). Moreover, the inter-site comparison of fold-
change results obtained from these data shows a correla-
tion coefficient of 0.976 (Figure 2C). Since the two test
sites used two different models of real-time PCR thermal
cyclers from Applied Biosystems for the above compari-
son, we investigated if the use of different real-time PCR
instruments could contribute to the differences in the CT
and fold-change results. We compared the gene expres-
sion results obtained using three different real-time PCR
thermal cycler models from different manufacturers (ABI
7500, Stratagene Mx3000P™ and BioRad iCycler iQ™) and
found that the correlations observed among different
models of real-time PCR instruments are similar to those
between the two test sites (data provided in Additional file
2).
Cross-platform Comparisons with Other Technologies
To evaluate the concordance of fold changes between
SYBR Green PCR Arrays and other technologies evaluated
in the MAQC study, we performed regression analyses of
fold differences in sample B compared to sample A for all
genes common between the custom RT2  Profiler PCR
Arrays and another platform. In addition, a list of differ-
entially expressed genes (DEGs) was identified for each
platform between the two reference RNA samples using
the cut-off criteria of a P  value less than 0.05 by an
unpaired  t-test with a mean difference greater than or
equal to 2-fold, and the lists of DEGs from different plat-
forms were compared.
Inter-site comparison of RT2 Profiler PCR Arrays Figure 2
Inter-site comparison of RT2 Profiler PCR Arrays. 
Threshold cycle measurements and fold-change results have 
been obtained using the two MAQC reference RNAs ana-
lyzed on the Human Drug Metabolism RT2 Profiler PCR 
Array (APH-002) using different real-time PCR thermal 
cyclers at two different sites. Five replicate arrays were run 
for each sample at each site, and the average CT value for 
each assay is compared between the two sites in panels A 
and B. The results show a high correlation between CT values 
obtained from the two sites. Panel C shows the inter-site 
comparison of fold-change results obtained from these data, 
indicating a correlation coefficient of 0.976.
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Assay precision of SYBR Green RT2 Profiler PCR Arrays Figure 1
Assay precision of SYBR Green RT2 Profiler PCR 
Arrays. The plot shows the coefficient of variation for each 
average CT value. A total of 184 average CT measurements 
were obtained from Sample A and Sample B. Each average CT 
value and its coefficient of variation were calculated from the 
result of 6 replicate assays.
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Table 2: The average standard deviation for different CT value 
ranges and the percentage of genes in each group (percent 
frequency)
CT Values Ave SD Frequency (%)
10–25 0.11 45
25–30 0.19 41
30–35 0.40 11
≥ 35 0.96 3
Not Detectable 0 0
A total of 184 average CT measurements were obtained from Sample 
A and Sample B. Each average CT value and its standard deviation 
were calculated from the result of 6 replicate assays.BMC Genomics 2008, 9:328 http://www.biomedcentral.com/1471-2164/9/328
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Fold-change correlation between PCR Arrays and other quantitative 
platforms
SYBR Green RT2 Profiler™ PCR Arrays display high con-
cordance with TaqMan, QuantiGene and StaRT-PCR in
measuring fold differences between Sample A and Sample
B. Data from regression analysis show that the correlation
coefficient R and slope for RT2 Profiler PCR Arrays versus
TaqMan are 0.97 and 0.99, respectively; for RT2 Profiler
PCR Arrays versus QuantiGene are 0.93 and 0.75, respec-
tively; and for RT2 Profiler PCR Arrays versus StaRT-PCR
are 0.91 and 0.98, respectively (Figure 3 and Table 3). RT2
Profiler PCR Arrays are shown to be best correlated with
TaqMan assays (R = 0.97). When these results are com-
pared with the MAQC data sets, similar fold-change corre-
lations versus QuantiGene and StaRT-PCR are noted for
both RT2 Profiler PCR Arrays and TaqMan (Table 3). Fold-
change results between Sample A and Sample B from all
four quantitative platforms and the lists of differentially
expressed genes (DEGs) generated using the pre-set crite-
ria (fold change ≥ 2, P < 0.05) are compared. PCR Arrays
display a high percentage of cross-platform overlap with
the other quantitative platforms, ranging from 81% to
93%.
Fold-change correlation between PCR Arrays and microarray 
platforms
Results from regression analysis showed a good linear cor-
relation in the log2 fold change data between SYBR Green
PCR Arrays and the five microarray platforms (AFX, AG1,
ABI, GEH and ILM) selected for this study (Figure 4 and
Table 4; see Additional file 3 for the individual scatter plot
for each comparison). The correlation coefficients and lin-
ear slopes for the comparison between PCR Arrays and
different microarray platforms are as follows: 0.95 and
0.62, respectively, for AFX; 0.94 and 0.78, respectively, for
AG1; 0.90 and 0.61, respectively, for ABI; 0.86 and 0.56,
respectively, for GEH; and 0.92 and 0.60, respectively, for
ILM. The above results from these cross-platform compar-
isons with microarrays are very similar to those obtained
from TaqMan as seen in the MAQC project (Table 4). The
overlap in the lists of DEGs between PCR Arrays and each
of the five microarrays is also high, yielding a 73% to 90%
range.
Discordant gene analysis
Comparisons between the fold-change results of the SYBR
Green PCR Arrays and those of the other platforms reveal
discordance in a few genes (Table 5). We define a gene to
be discordant if the gene exhibits changes in the opposite
direction with PCR Arrays and another platform being
compared, and at least one of these two platforms indi-
cates the gene to be differentially expressed (i.e. a twofold
or greater change with a p-value less than 0.05). By these
criteria, two genes, FURIN and RB1, are found discordant
between PCR Arrays and the other quantitative platforms
(Table 5). TaqMan shows a fold change of -43.98 for
FURIN but PCR Arrays indicate a fold change of 1.16 for
this gene. StaRT-PCR, QuantiGene and the five microarray
Table 3: Fold-change correlation between the four different quantitative gene expression analysis platforms
Correlation (R)  TaqMan QuantiGene StaRT-PCR
(Number of genes in comparison)
RT2 Profiler PCR Array 0.97 (86) 0.93 (76) 0.91 (57)
TaqMan 0.90* (181) 0.94* (92)
QuantiGene 0.92* (53)
*Correlation R values derived from the data provided by MAQC studies [8]
Cross-platform comparison between SYBR Green RT2 Pro- filer PCR Arrays and the three quantitative platforms Figure 3
Cross-platform comparison between SYBR Green 
RT2 Profiler PCR Arrays and the three quantitative 
platforms. The concordance of fold-changes between the 
PCR Arrays and the three quantitative platforms was evalu-
ated by regression analysis of fold differences in sample B 
compared to sample A. Data were normalized against 
POLR2A for RT2 Profiler PCR Arrays and TaqMan, and against 
beta-actin for StaRT-PCR. The sample B/sample A (B/A) fold 
changes (log2) for each gene common between RT2 Profiler 
PCR Arrays and another platform were subjected to bivari-
ate analysis. The dashed line on each graph represents the 
ideal slope of 1.0. The solid lines show a linear regression fit.
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platforms show a fold change ranging from -1.49 and 1.04
for  FURIN. Hence, no difference in the expression of
FURIN between Samples A and B is observed with any
platforms except TaqMan.
The other discordant gene, RB1, exhibits a fold change of
1.73 with PCR Arrays but a fold change of -3.09 with
QuantiGene. TaqMan and StaRT-PCR indicate fold
changes of -1.92 and -1.59, respectively, for RB1. All of the
five microarray platforms show negative fold changes
with four of the platforms indicating a twofold or greater
change. Interestingly, the RB1 gene was originally indi-
cated by PCR Arrays to be absent (CT > 35) in both sam-
ples A and B. This finding was in contrast to the results
from the other three quantitative platforms where the
gene was considered to be present and moderately to
highly expressed in both RNA samples [8]. This discrep-
ancy was later found to arise from the probing location of
the primers for RB1 in PCR Arrays being based on a former
version of the RefSeq accession (NM 000321.1) which
had been revised to the current RefSeq release (NM
000321.2) on June 9, 2006. The revised RefSeq accession
revealed a two-base mismatch (from C-G to G-C) with the
former version in the region where one of the RB1 primers
for PCR Arrays happened to recognize. Upon repeating
the assays using the RB1 primer with the revised sequence,
the RB1 gene is now considered to be present with an aver-
age CT value of around 23–25 in both samples. Results
generated from this new RB1 assay show a fold change of
-1.75 for this gene, which is in agreement with TaqMan
and StaRT-PCR, and have replaced the data obtained from
the old RB1 assay for the rest of the data analyses in this
study.
Six other discordant genes besides RB1 are noted between
SYBR Green PCR Arrays and the five microarray platforms
(Table 5). Of those six discordant genes, one gene with
AFX, four with ABI, two with AG1, and one with GEH, dis-
play changes in the opposite direction when compared to
the RT2 Profiler PCR Array. BAG1 exhibits a fold change of
1.66 with PCR Arrays but a fold change of -2.89 with AFX
while the other platforms indicate the gene to be similarly
expressed in both RNA samples with a minimal fold
change from -1.97 to 1.85. CDK5R1  and  IGFBP5  are
shown to be discordant between ABI and PCR Arrays, with
the directions of fold-change observed by ABI for these
two genes to be opposite to those reported by all other
platforms. ABCD1 and BAG4 are discordant within the
five microarray platforms while the three quantitative
platforms that have measured these two genes, the RT2
Profiler PCR Array, TaqMan and QuantiGene, show fold-
change values in a uniform direction. JAK2 displays a fold
change of -1.15 by AG1 but 2.11 by PCR Arrays. All other
platforms show the same direction of fold-change as PCR
Arrays; however, like AG1, all of them indicate no signifi-
cant difference in JAK2 expression between the two RNA
samples with a fold change smaller than two.
Table 4: Fold-change correlations between SYBR Green RT2 Profiler PCR Arrays or TaqMan assays and the five microarray platforms
Correlation (R)  AFX AG1 ABI GEH ILM
(Number of genes in comparison)
PCR Array 0.95 (89) 0.94 (86) 0.90 (89) 0.86 (88) 0.92 (87)
TaqMan* 0.92 (451–472) 0.91 (532–595) 0.85 (523–567) 0.85 (660–670) 0.91 (484–516)
*The average correlation R values and the number of genes in comparison for three sites are derived from the data provided by MAQC studies 
[12].
Cross-platform comparison between SYBR Green RT2 Pro- filer PCR Arrays and microarray platoforms Figure 4
Cross-platform comparison between SYBR Green 
RT2 Profiler PCR Arrays and microarray platoforms. 
The concordance of fold-changes between the PCR Arrays 
and microarray platforms was evaluated by regression analy-
sis of fold differences in sample B compared to sample A. 
Data were normalized against POLR2A for RT2 Profiler PCR 
Arrays. The sample B/sample A (B/A) fold changes (log2) for 
each gene common between RT2 Profiler PCR Arrays and 
another platform were subjected to bivariate analysis. The 
dashed line on the graph represents the ideal slope of 1.0. 
Each solid line represents the linear regression fit. The num-
bers in brackets indicate the number of common genes 
between RT2 Profiler PCR Arrays and each microarray plat-
form. The individual scatter plot for each comparison is pro-
vided in Additional file 3.
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Discussion
Although SYBR Geen PCR is a popular gene expression
technique used by about half of the real-time PCR users, it
was surprisingly not evaluated in the MAQC study. There-
fore, in this study, we have assessed the performance of
SYBR Green RT2 Profiler PCR Arrays and compared our
expression profiling results of those two reference samples
with the MAQC results obtained from three other tradi-
tional quantitative platforms including TaqMan assays,
QuantiGene and StaRT-PCR as well as five commercial
microarrays.
The present study demonstrates SYBR Green RT2 Profiler
PCR Arrays to be a quantitative platform with high inter-
run and inter-laboratory reproducibility. The average CV
for the CT values generated from all assays on the custom
PCR Array is found to be 0.73% with replicate measure-
ments for CT values below 30 within 0.20 cycle average
standard deviation, demonstrating a good inter-run repro-
ducibility. When compared with the results from the other
three quantitative platforms studied in the MAQC study
(Additional file 1), the transformed data based on the cor-
responding universal MAQC scale give a median CV for all
assays on PCR Arrays of 0.89% and that for assays detect-
ing > 6000 transcript copies of 0.57%. These respective
values were reported to be 3.46% and 2.42% for TaqMan,
6.26% and 3.82% for StaRT-PCR, and 2.16% and 2.12%
for QuantiGene [8]. As seen with TaqMan assays and
StaRT-PCR [8], a trend of increasing CV and SD is
observed with increasing CT  values (i.e. decreasing
amount of transcripts) which is attributable to the sto-
chastic nature of the sample loading of transcript mole-
cules which influences the magnitude of CV [8]. High
level of inter-site reproducibility is also demonstrated for
SYBR Green PCR Arrays by inter-site comparison of CT val-
ues and fold-change results leading to correlation coeffi-
cients of 0.97 and 0.98, respectively.
Results obtained from SYBR Green PCR Arrays show that
83 out of the 90 selected genes (92%) are considered to be
present in both samples A and B, which is similar to the
values reported in the MAQC study for the detection sen-
sitivity of the other three quantitative platforms [8].
Eighty-six percent (86%), 94% and 91% of the tested
genes were above the respective LOD of the TaqMan assay
(857 out of 997 tested genes), StaRT-PCR (193 out of 205
tested genes) and QuantiGene (223 out of 244 tested
genes) in both samples A and B [8]. The assay range of
PCR Arrays is 8.6 on a log10 scale, which is comparable to
the assay range of 8.1 for TaqMan assay reported in the
MAQC project [8] and wider than those of the other two
quantitative platforms in the MAQC study, with StaRT-
PCR and QuantiGene having an assay range of 6.8 and
4.1, respectively [8].
Cross-platform comparisons of gene profiling results of
the two MAQC reference RNA samples illustrate a remark-
ably good correlation between SYBR Green RT2 Profiler
PCR Arrays and other technologies tested in the MAQC
studies. Specifically, PCR Arrays and the other two PCR-
based methods, TaqMan and StaRT-PCR, exhibit an
exceedingly high concordance with values for their corre-
lation coefficients and linear slopes close to 1. This result
demonstrates that these three methods report very similar
fold changes in gene expression between the two MAQC
samples. Although high correlation coefficients are
observed between PCR Arrays and the hybridization-
based techniques such as QuantiGene and the microar-
rays, the values for the linear slope are lower, ranging from
0.56 to 0.78. These results are consistent with a compres-
sion effect on log2 fold change computed from the hybrid-
ization-based techniques which was also observed when
comparisons between TaqMan PCR and QuantiGene or
microarray platforms were made in the MAQC studies
[8,12].
SYBR Green real-time PCR Arrays demonstrate a good
concordance in the differentially expressed gene list with
the three quantitative technologies and five microarray
platforms examined in the MAQC projects. Great overlaps
Table 5: Comparison of fold-change results on the discordant genes between SYBR Green PCR Arrays and other platforms
RT2 Profiler PCR Array TaqMan StaRT-PCR QuantiGene AFX ABI AG1 GEH ILM
FURIN 1.16 -43.98 -1.49 -1.42 -1.21 1.04 -1.38 N/A -1.12
RB1 1.73* -1.92 -1.59 -3.09 -2.23 -1.30 -4.06 -2.14 -2.14
ABCD1 -5.44 -7.11 N/A -3.83 -1.45 2.21 -8.25 2.15 -2.41
BAG1 1.66 -1.06 1.85 -1.97 -2.89 -1.00 1.12 -1.01 1.18
BAG4 2.66 1.01 N/A 1.96 1.30 -2.25 -2.25 1.13 1.51
CDK5R1 45.53 28.92 N/A 21.55 18.11 -1.09 1.56 2.11 14.26
IGFBP5 -1.68 -2.69 -1.98 -2.16 -2.68 4.11 -3.26 -2.42 -2.37
JAK2 2.11 1.31 N/A 1.25 1.06 1.11 -1.15 1.99 1.06
Fold-change values for the above platforms other than RT2 Profiler PCR Arrays are derived from the data provided by MAQC studies [8,12]. A 
positive value for fold change indicates a higher expression while a negative value indicates a lower expression in Sample B when compared with 
Sample A. "N/A" means the gene was not included in the indicated platform. Discordant fold-change values compared to RT2 PCR Arrays are 
underlined and in bold. *The fold-change value for RB1 gene from the PCR Array using the corrected sequence is -1.75 (see text for details).BMC Genomics 2008, 9:328 http://www.biomedcentral.com/1471-2164/9/328
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in the list of DEGs are noted for PCR Arrays and TaqMan
as well as the other quantitative platforms, ranging from
81% to 93%. The list of DEGs generated by PCR Arrays is
also highly comparable with the five microarray plat-
forms, with overlaps ranging from 73% to 90%. However,
disparities in the expression results are observed for two
genes between PCR Arrays and quantitative platforms,
and for six genes in addition to RB1 between PCR Arrays
and the five microarray platforms (Table 5). One possible
cause for the disparities was experimentally investigated
and found due to the accuracy of sequence information
provided by the NCBI RefSeq database. As the design of
the primers and probes for gene expression measurement
is usually based on the gene sequence information from
the RefSeq and non-RefSeq databases, any inaccuracies in
those databases or the presence of previously unknown
SNPs or splice variants, will potentially affect the accuracy
of the assays. This scenario was clearly illustrated by the
SYBR Green assay for RB1 gene in this study where the dis-
covery of a two-base mismatch in one of the RB1 primers
was made with the current RefSeq accession. Since the Ref-
Seq database is frequently being updated to improve the
accuracy of its gene sequence information, it is important
to have the sequences of the primers and probes checked
periodically against the most updated version of the Ref-
Seq database in order to ensure the accuracy of the assays.
Because we have limited access to the information on the
exact sequences of the primers and probes used by other
technologies and platforms, it is difficult to investigate
further all of the potential causes of the discordances
between platforms by performing experiments. Another
possible explanation for the discordance may be due to a
difference in the interrogative regions [8]. The MAQC
study provides the information on the approximate
regions being probed in individual assays for all tested
platforms in the form of the distance from the most 3'
location of each assay to the 3' end of the gene [12]. Com-
parisons of the detection regions between different tech-
nologies are listed in Table 6 and shown in Figure 5.
FURIN is found to be differentially expressed by TaqMan
assays [8] but not by other platforms; this appears to be
due to a difference in the regions being probed, with the
TaqMan assay interrogating a region that is closer to the 5'
end of the gene than those of other platforms [8] (Table 6
and Figure 5). The same explanation could also be sug-
gested for RB1, JAK2, BAG1 and BAG4. For RB1 and JAK2,
the locations being probed for PCR Arrays are closer to the
5' end of these genes than those of other platforms. Simi-
larly, the discordance against other technologies in the
fold-change results for BAG1 with AFX, and BAG4 with
ABI and AG1, might be due to the fact that these platforms
interrogate a region closer to the 3' end of these two genes
than all other platforms.
The discrepancies in the expression results for the remain-
ing three genes (ABCD1, CDK5R1 and IGFBP5) cannot
simply be explained by the difference in probe locations.
Interestingly, while these three genes display discordance
among the microarray platforms, all four quantitative
platforms show comparable results. This has led to the
suggestion that disagreements between microarray plat-
forms may be due to cross-hybridization of the probes on
the arrays with other targets [8]. As in the case of RB1, the
underlying reason for the discordance caused by different
detection regions among technologies and platforms may
be associated with the degree of accuracy in the sequence
information being varied at different regions due to the
continuous discoveries of previously unknown SNPs and
spliced variants. Hence, even if the primers or probes from
different platforms recognize the same region, there is a
possibility that they may detect different spliced variants
or transcripts with different SNPs. Again, frequently
updating the primer and probe design with the most
Comparison of the probing locations for the discordant  genes between RT2 Profiler PCR Arrays and other gene  expression measurement platforms in the MAQC phase 1  study Figure 5
Comparison of the probing locations for the discord-
ant genes between RT2 Profiler PCR Arrays and 
other gene expression measurement platforms in 
the MAQC phase 1 study. The diagram illustrates the 
most 3' interrogative locations of the assays of different plat-
forms for the eight discordant genes discussed in the text 
and shown in Table 6. The black lines represent, from left to 
right, the 5' to 3' position of the genes, each indicated with 
the length of the transcript. The assay location of each plat-
form is indicated by a letter above the black line (A = RT2 
Profiler PCR Array; B = TaqMan; C = StaRT-PCR; D = Quan-
tiGene; E = AFX; F = ABI; G = AG1; H = GEH; and I = ILM). 
Assays with discordant results compared to those of PCR 
Arrays are highlighted in grey.BMC Genomics 2008, 9:328 http://www.biomedcentral.com/1471-2164/9/328
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updated releases of RefSeq and non-RefSeq databases is
essential for the success of all of these technologies.
Disagreements between different platforms may also arise
from low detection signals for some genes. Among the dis-
cordant genes noted in Table 5, BAG4 and CDK5R1 are
considered by all the five microarray platforms to be
either absent or having relatively low expression in at least
one of the two RNA samples. This trend with discordance
occurring more frequently with low expressers was also
noted in the MAQC study [8].
Conclusion
In summary, SYBR Green real-time PCR Arrays produce
gene profiling differences between the two MAQC refer-
ence RNA samples that are highly concordant with those
generated by other quantitative gene expression analysis
and microarray platforms. PCR Arrays deliver results com-
parable to those of high-density microarrays. Moreover, it
yields results similar to those of TaqMan Gene Expression
Assays, a widely accepted method for validating microar-
ray results, and other more complicated and more expen-
sive quantitative methods tested by the MAQC project.
Hence, SYBR Green PCR Array is a quantitative platform
suitable for microarray data validation.
Methods
Materials
Sample A (Universal Human Reference RNA) and Sample
B (Human Brain Reference RNA), were purchased from
Stratagene (Cat# 740000 lot#1130623; La Jolla, CA) and
Ambion (Cat# 6050 lot#105P055201A; Austin, TX),
respectively. Both of these reference RNA samples are
from the identical manufacturing lots as those used in the
MAQC study [8,12]. Reverse transcription kits (Cat# C-
01) and SYBR Green real-time PCR master mixes (Cat#
PA-012 and Cat# PA-011) were from SuperArray Bio-
science (Frederick, MD). The Human Drug Metabolism
RT2 Profiler™ PCR Array (Cat# APH-002), that was used
for inter-site and inter-instrument comparison, and a cus-
tom RT2 Profiler PCR Array (Table 1), that was used for
cross-platform comparison, were designed and manufac-
tured at SuperArray with the primer sets for the specified
genes pre-dispensed into a 96-well PCR plate.
Cross-platform comparison
The custom PCR Array designed for cross-platform com-
parison was run in six technical replicates for each of the
two MAQC reference RNAs. For each custom PCR array,
one microgram (μg) of RNA was reverse transcribed in a
20-μL reaction volume into first-strand cDNA using
SuperArray's ReactionReady™ First Strand cDNA Synthesis
Kit (Cat# C-01) containing random primers following the
instructions provided in the user's manual. After mixing
the cDNA with RT2 SYBR Green/ROX qPCR Master Mix
(Cat# PA-012, SuperArray), 25 μL of the mixture contain-
ing cDNA synthesized from 9 ng total RNA was dispensed
to each well of PCR Arrays. This amount of sample input
is similar to the 10 ng total RNA sample input per reaction
for TaqMan and StaRT-PCR Assays but lower than the 500
ng total RNA input per reaction for QuantiGene per-
formed in the MAQC phase 1 study. Real-time PCR was
performed on an ABI 7500 Real-Time PCR System
(Applied Biosystems, Foster City, CA) using the following
cycling parameters: 10 min at 95°C (heat activation step);
40 cycles of 15 sec at 95°C, 1 min at 60°C. Dissociation
curve analyses were performed using the instrument's
default setting immediately after each PCR run.
Inter-site comparison
The two MAQC reference RNAs were analyzed on the
Human Drug Metabolism RT2 Profiler™ PCR Array (Cat#
APH-002) at two different locations with cDNA synthesis
and PCR procedures performed as described above. PCR
Arrays were performed on an ABI 7500 Real-Time PCR
System at Site 1 while the arrays were run on an ABI 7000
Table 6: Comparison of the probing locations for the discordant genes between RT2 Profiler PCR Arrays and other gene expression 
measurement systems in the MAQC study
Gene Length (Bases) RT2 Profiler PCR 
Array
TaqMan StaRT-PCR QuantiGene AFX ABI AG1 GEH ILM
FURIN 4180 2060 4115 1382 2048 65 1 632 N/A 184
RB1 4740 4268 2068 1742 2053 46 171 119 1322 1471
ABCD1 3616 1139 2317 N/A 2292 104 565 314 355 102
BAG1 3858 3143 3319 2675 2750 148 3381 2597 2614 2718
BAG4 2182 941 1618 N/A 924 584 52 281 1774 802
CDK5R1 3870 2823 3597 N/A 2905 41 2948 2782 3403 689
IGFBP5 6316 4845 5198 5519 5074 411 4868 418 5882 4740
JAK2 5097 4761 1409 N/A 2216 36 612 1164 316 323
The most 3' interrogative locations of the above assays are indicated by the distance to the 3' end of the corresponding gene. The probing locations 
of the assays for technologies other than RT2 Profiler PCR Arrays are available from the supplementary information provided by the MAQC study 
[8,12]. Assays with discordant results compared to those of PCR Arrays are underlined and in bold.BMC Genomics 2008, 9:328 http://www.biomedcentral.com/1471-2164/9/328
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at Site 2, with both sites using SuperArray's RT2 SYBR
Green/ROX qPCR Master Mix (Cat# PA-012). Five repli-
cate arrays were run for each sample at each site.
Data normalization and analyses
The threshold cycle number (CT) for each PCR reaction is
determined by setting the same threshold value across all
PCR Arrays. For data normalization in the custom PCR
Arrays, POLR2A was selected as the reference endogenous
control gene since it was used as the normalizer in the
TaqMan Assay in the MAQC study [8]. POLR2A was meas-
ured on each array plate in triplicate assays. The compara-
tive CT  method was used to calculate relative
quantification of gene expression as described previously
[21]. The relative amount of transcripts for each gene in
Sample A and Sample B was normalized to the reference
gene POLR2A and calculated as follows: ΔCT is the log2 dif-
ference between the gene and the reference gene, and is
obtained by subtracting the average CT of POLR2A from
the CT value of the gene on a per array basis; the log2 fold
change between the two samples was obtained using the
formula: ΔΔCT = the average Δ CT of Sample B – the aver-
age Δ CT of Sample A, and their fold difference = 2-ΔΔ CT.
For cross-platform comparison, normalized data for both
Sample A and Sample B from the other gene expression
analysis technologies were directly obtained from pub-
lished results [8,12] and from the database accessible
from the MAQC website [20]. For each gene, the fold
change between the two samples was generated by calcu-
lating the ratio of the average of the normalized signals for
all sample B replicates to the average of the normalized
signals for all sample A replicates. The sample B/sample A
(B/A) fold changes (log2) for all genes common between
the RT2 Profiler PCR Arrays and another platform were
compared and subjected to bivariate regression analysis,
and Pearson correlation coefficients (R) were computed
for each cross-platform comparison. For inter-site and
cross-instrument comparison, data normalization in the
Human Drug Metabolism RT2 Profiler™ PCR Array was
carried out as instructed in the user's manual using the
mean CT  of five housekeeping genes as the reference
endogenous control for each array plate. The ΔΔCT and
fold-change values between the two RNA samples for each
gene on the array plate were obtained and compared
between the two sites and across different real-time PCR
thermal cyclers.
Sensitivity detection and differentially expressed genes 
(DEG) determination
PCR Array quantification is determined by CT numbers. A
gene is considered absent when the average CT exceeds 35.
The CT is marked as 35 for the Δ CT calculation when the
signal is below the limit of quantitation (this is referred to
as the limit of detection (LOD) in the MAQC study [8]). A
list of DEGs between the two reference RNA samples was
identified using the cut-off criteria of a P value less than
0.05 as assessed by an unpaired t-test with a mean differ-
ence greater than or equal to 2-fold.
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